Ibogaine for Sale Online

The short answer, before the detail

Ibogaine cannot be lawfully bought, sold, shipped or possessed in the United States. It sits in Schedule I of the Controlled Substances Act, listed by name, and there is no FDA-approved ibogaine product for any condition. Ordering it from abroad is a separate federal offence under the importation statute, and the exposure falls on the person receiving the parcel. Beyond the law, the product itself is the problem: nothing sold outside a regulated medical supply chain is subject to FDA manufacturing oversight or any pharmacopeial standard, and the one published analysis of iboga products found the ibogaine content varying by more than a hundredfold between preparations. Ibogaine is dosed by body weight, so an unknown concentration is an unknown dose, and ibogaine's known cardiac effect is dose dependent.

• Schedule I in the US: 21 CFR 1308.11(d)(21), DEA drug code 7260
• Importing a Schedule I substance without DEA registration: 21 U.S.C. 952
• No FDA-approved ibogaine product exists for any indication
• Ibogaine content across 16 tested products: 0.6% to 73.4% (Bouso et al., 2020)
• One of those 16 products contained no iboga alkaloids at all
• Cardiac risk window outlasts the experience: noribogaine half-life 28 to 49 hours

Why there is no legal seller, anywhere in the United States

Ibogaine is listed by name in Schedule I of the US Controlled Substances Act, at 21 CFR 1308.11(d)(21), under DEA drug code 7260. The entry names both the compound and Tabernanthe iboga, the plant it comes from. Schedule I is the category for substances the federal government has determined have no currently accepted medical use in treatment in the United States, and there is no FDA-approved ibogaine product for any indication. That combination closes every legal route: no prescription can be written, no pharmacy can dispense it, and no retailer can lawfully sell it.

Ordering from an offshore vendor does not route around this. Under 21 U.S.C. 952 it is a federal offence to import a Schedule I substance into the United States except by a person registered with the DEA who holds an import permit for that specific shipment. There is no version of that permit available to a private individual. International mail and parcel shipments are covered, which is how essentially all online ibogaine orders travel. The legal exposure attaches to the person the package is addressed to, not to the website that took the payment.

It is worth being precise about what this does and does not mean, because the noise on this topic is considerable. Schedule I is a statement about US regulatory status, not a verdict on the science, and ibogaine is the subject of legitimate ongoing research and state-funded clinical trial programmes. Its status also differs sharply by country: it is a prescription medicine in New Zealand, it sits on Health Canada's Prescription Drug List with no approved product to prescribe, and it is not a scheduled substance in Mexico, which is why medically supervised clinics operate there lawfully. We keep the country-by-country picture current on ibogaine legal status and track legislation on the policy tracker, because it keeps changing.

The only published analysis of iboga products found a hundredfold spread

In 2020, Bouso and colleagues published a GC/MS analysis of 16 iboga samples in Archives of Clinical Psychiatry. These were not random dark-web purchases. They were products obtained from ibogaine treatment providers, which is to say the better end of the supply. The results were still striking.

Root bark preparations contained between 0.6 and 11.2 percent ibogaine. Total alkaloid extracts ran from 8.2 to 32.9 percent. Products sold as purified ibogaine hydrochloride, the form clinical protocols are written around and which should assay in the region of 90 percent, came in between 61.5 and 73.4 percent. A single purified total alkaloid sample reached 73.7 percent. One sample, sold as an iboga product, contained no iboga alkaloids whatsoever. Other alkaloids and unidentified substances were present in almost all of them. The authors concluded plainly that the purity of iboga products is highly variable.

The reason this matters more for ibogaine than it would for many substances is that ibogaine is dosed by body weight. A protocol is written as milligrams per kilogram, and that arithmetic only works if you know the concentration of what is in the container. A root bark preparation at 11.2 percent delivers close to nineteen times the alkaloid load of one at 0.6 percent for the same measured quantity. A product labelled hydrochloride that assays at 61.5 percent rather than the roughly 90 percent expected of the pure salt breaks the calculation in the other direction. We wrote out why the salt form alone already changes the arithmetic in total alkaloid extract versus hydrochloride, and what a real identity confirmation looks like in the chemical structure reference.

There is a regulatory point underneath the analytical one. Nothing sold outside a licensed medical supply chain is subject to FDA manufacturing oversight, current Good Manufacturing Practice, or any pharmacopeial standard, because an illegal substance has no regulator inspecting it. A certificate of analysis supplied by the seller is a document the seller wrote. Unless it names the salt form, states the analytical method, and references a certified reference standard, it has confirmed nothing.

Why an unknown ibogaine dose is a different kind of unknown

Ibogaine blocks the hERG potassium channel. hERG carries the rapid delayed-rectifier current that repolarises heart muscle after each beat, and blocking it lengthens the QT interval on an EKG. A sufficiently prolonged QT interval can degenerate into torsades de pointes, a ventricular arrhythmia that can be fatal. This is a property of the molecule, it is dose dependent, and it is not in dispute.

Koenig and Hilber set this out in a 2015 review in Molecules. They reported hERG block at around 4 micromolar, a concentration that is reached in human plasma at commonly used doses, and made a comparison that is worth sitting with: ibogaine's cardiac profile closely resembles that of cisapride and astemizole, two drugs that were approved, marketed, and then withdrawn specifically because of their propensity to induce torsades. Those were regulated pharmaceuticals of known purity, taken at prescribed doses, and they were still too dangerous to leave on the market.

The timing is the part people get wrong. Ibogaine's own half-life is short, in the region of 2 to 6 hours. The liver converts it via CYP2D6 into noribogaine, whose half-life is reported at 28 to 49 hours and which also inhibits hERG channels and prolongs the cardiac action potential. Koenig and Hilber describe noribogaine as potentially the major proarrhythmic factor precisely because it persists. In practice the cardiac risk window extends well past the point where the psychoactive effects have faded. Somebody who feels themselves again, feels relieved, and goes to bed alone is still inside it. This is the whole reason cardiac screening and continuous monitoring are structural to a real protocol rather than a formality bolted on at the front.

Individual variation compounds it. Because CYP2D6 does the conversion, people who are poor metabolisers at that enzyme clear ibogaine much more slowly, reach higher and longer-lasting plasma concentrations, and, since plasma ibogaine concentration tracks with QTc prolongation, experience more pronounced and more prolonged QT effects from the same dose. The published recommendation is lower, individualised dosing guided by genotyping. A standard dose is not a standard exposure, and there is no way to know which category you are in without the test. We cover that in CYP2D6 and ibogaine metabolism.

What the published deaths actually have in common

The reference case series is Alper, Stajic and Gill, published in the Journal of Forensic Sciences in 2012. They reviewed 19 fatalities that occurred between 1.5 and 76 hours after ibogaine ingestion, across the years 1990 to 2008. In the 14 cases where postmortem data was adequate to reach a conclusion, advanced pre-existing medical conditions, mainly cardiovascular, and or one or more commonly abused substances explained or contributed to the death in 12 of them. The authors found no characteristic syndrome of neurotoxicity.

It is important not to overstate what that paper says, and equally important not to understate it. It is a case series, not an incidence rate, and it does not tell you the risk per exposure. What it does describe, quite specifically, is the profile of who died: people with heart disease that had not been found, and people with other drugs still in their system. That is not an argument that ibogaine is uniformly lethal. It is a description of exactly the two things a pre-treatment screen is built to detect, in people who did not have one.

The more recent literature points the same way on the mechanism. Ona and colleagues published an updated systematic review of adverse events in humans in Psychopharmacology in 2021, covering 2015 to 2020. Adverse events were highly heterogeneous, and QTc prolongation was the most common serious event reported. The signal has been consistent for over a decade: the danger is cardiac, it is findable in advance, and finding it requires equipment and someone qualified to read the output.

We publish our own safety record and how we measure it rather than asking anyone to take a general reassurance on trust. That is on measurable recovery and the safety guide. Ibogaine is investigational. It is not FDA approved for any indication, and no honest programme promises anyone an outcome.

Six checks that either happen in a clinic or do not happen

People search for ibogaine to buy because supervised treatment is expensive

It would be dishonest to write this page without saying the obvious thing out loud. Most people typing ibogaine for sale into a search engine are not looking for a legal loophole. They are looking at the cost of a medically supervised programme, or at a waiting list, or at a family member who is deteriorating faster than either, and they are trying to find a way through. That is a reasonable thing to be doing, and treating it as recklessness rather than desperation would be both unkind and inaccurate.

What we can do is be transparent about the cost rather than making people write in to find out. Our pricing is published on plans and pricing, the full breakdown of what the money buys and how programmes differ is on the cost guide, and financing options exist for people who need to spread it. Most of the cost is not the compound. It is the cardiology workup, the monitored medical bed, the staffing ratio through the night, and the days on either side.

That is also the reason the cheap route is not the same product at a lower price. The line item you would be removing is the monitoring, which is the part that makes the difference between a treatable arrhythmia and a fatal one. If cost is the barrier, the useful conversation is about financing, timing, or a different programme length. It is not about sourcing the molecule yourself.

The supply side, and why authentic Gabonese root bark is usually neither

Ibogaine occurs naturally in the root bark of Tabernanthe iboga, a shrub native to west central Africa, where it has been used ceremonially for generations and holds real cultural significance in Gabon. That context is part of why the supply chain is constrained rather than incidental to it.

In 2000, Gabon's Council of Ministers declared Tabernanthe iboga a national treasure. In 2019, the Gabonese government suspended the export of iboga, leaving only privately cultivated material with the correct permits eligible to leave the country. The IUCN Red List currently assesses the species as Least Concern, but records overharvesting, poaching, deforestation and declining seed dispersal as active pressures on wild populations. A vendor advertising wild-harvested Gabonese root bark shipped worldwide is describing something that either was not lawfully exported or is not what it is being sold as.

There is a legitimate botanical alternative that explains why most pharmaceutical-grade material is semi-synthetic rather than wild-harvested. Voacangine, from Voacanga africana, is a related alkaloid available at workable yield and is the usual starting material for semi-synthesis. That route does not deplete iboga populations. We cover the plant, its ecology and the conservation picture properly on the iboga plant and the individual compounds in the alkaloid encyclopedia.

The pages worth reading before you do anything

Validated instruments build your baseline before you travel.

Our medical team is with you around your session, on dedicated professional equipment.

Your progress re-scored against your baseline, in your portal.

Common questions

100% Confidential · No Obligation